Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof

a technology of which is applied in the field of modified hematopoietic stem/progenitor and non-t effector cells, can solve the problems of lethal delay in treatment, and achieve the effect of removing delays and expense in treatmen
US20160250258A1Inactive Publication Date: 2016-09-01SEATTLE CHILDRENS HOSPITAL +1
0 Cites 36 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
SEATTLE CHILDRENS HOSPITAL
Publication Date
2016-09-01
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Hematopoeitic stem / progenitor cells (HSPC) and / or non-T effector cells are genetically modified to express (i) an extracellular component including a ligand binding domain that binds a cellular marker preferentially expressed on an unwanted cell; and (ii) an intracellular component comprising an effector domain. Among other uses, the modified cells can be administered to patients to target unwanted cancer cells without the need for immunological matching before administration.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a national phase application which claims priority to International Patent Application No. PCT / US14 / 63576, filed on Oct. 31, 2014, which claims priority to U.S. Provisional Patent Application No. 61 / 898,387 filed on Oct. 31, 2013, the entire contents of both of which are incorporated by reference herein.FIELD OF THE DISCLOSURE

[0002] Hematopoeitic stem / progenitor cells (HSPC) and / or non-T effector cells are genetically modified to express (i) an extracellular component including a ligand binding domain that binds a cellular marker preferentially expressed on an unwanted cell; and (ii) an intracellular component comprising an effector domain. Among other uses, the modified cells can be administered to patients to target unwanted cancer cells without the need for immunological matching before administration.BACKGROUND OF THE DISCLOSURE

[0003] Significant progress has been made in genetically engineering T cells of the immune...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More